Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis.

Pediatr Gastroenterol Hepatol Nutr

Department of Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital, Houston, TX, USA.

Published: September 2016

Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061664PMC
http://dx.doi.org/10.5223/pghn.2016.19.3.210DOI Listing

Publication Analysis

Top Keywords

oral vancomycin
16
primary sclerosing
8
sclerosing cholangitis
8
ulcerative colitis
8
oral
4
vancomycin therapy
4
therapy child
4
child primary
4
cholangitis severe
4
severe ulcerative
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!